Literature DB >> 10579798

Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition.

Y Shibata1, K Ito, K Suzuki, K Nakano, Y Fukabori, R Suzuki, Y Kawabe, S Honma, H Yamanaka.   

Abstract

BACKGROUND: It is well-known that the incidence of benign prostatic hyperplasia (BPH) increases with aging. The age-dependent changes in the ratio of serum sex steroid concentrations may play a role in BPH development. To clarify the relationship between the prostatic tissue concentrations of these steroids and age, we established a precise method of simultaneous quantitative analysis for prostatic sex steroids and used this method to investigate the tissue concentrations of three major sex steroids (testosterone, dihydrotestosterone, and estradiol) in the human prostate.
METHODS: The methodology for the simultaneous quantitative analysis of prostatic sex steroids was established using castrated rat prostatic tissue, coupled with internal standards, for androgen-deprived medium, and the validation of the method was examined. Human prostatic tissues were collected during surgery and immediately frozen at -70 degrees C. Using our method, the steroidal fractions were extracted, purified, and quantified. The proportions of stroma, epithelium, and glandular lumen were measured on each histological specimen, using an image analyzer.
RESULTS: The validation tests showed that our method of quantitative analysis was precise and sensitive enough for the quantification of testosterone, dihydrotestosterone, and estradiol in the prostate. In humans, the prostatic dihydrotestosterone concentration decreased with age, but the concentrations of testosterone and estradiol showed no relation with age. Therefore, the ratio of estradiol to dihydrotestosterone concentration (E2/DHT) in prostate increased with age. The E2/DHT ratio showed a significant positive correlation with the proportion of stroma.
CONCLUSIONS: The age-dependent decrease in prostatic dihydrotestosterone and constant estradiol concentration lead to a relatively estrogen-dominant environment compared to that at younger ages. We assume that this relatively estrogen-dominant status induces stromal proliferation by some mechanism and leads to the development of BPH. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10579798     DOI: 10.1002/(sici)1097-0045(20000101)42:1<45::aid-pros6>3.0.co;2-w

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.

Authors:  Rajeev Kumar; Vikas Verma; Amit Sarswat; J P Maikhuri; Ashish Jain; Rajeev K Jain; V L Sharma; Diwakar Dalela; Gopal Gupta
Journal:  Invest New Drugs       Date:  2010-12-23       Impact factor: 3.850

Review 2.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

Review 3.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

4.  The differential effects of prostate stromal cells derived from different zones on prostate cancer epithelial cells under the action of sex hormones.

Authors:  Qi Jiang; Bang-Min Han; Fu-Jun Zhao; Yan Hong; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

5.  Metabolic factors associated with benign prostatic hyperplasia.

Authors:  J Kellogg Parsons; H Ballentine Carter; Alan W Partin; B Gwen Windham; E Jeffrey Metter; Luigi Ferrucci; Patricia Landis; Elizabeth A Platz
Journal:  J Clin Endocrinol Metab       Date:  2006-04-11       Impact factor: 5.958

6.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

Review 7.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

Review 8.  Prostate tissue androgens: history and current clinical relevance.

Authors:  Leonard S Marks; Elahe A Mostaghel; Peter S Nelson
Journal:  Urology       Date:  2008-05-27       Impact factor: 2.649

Review 9.  [Pathophysiology and therapy of benign prostatic hyperplasia].

Authors:  Natalie Sampson; Stephan Madersbacher; Peter Berger
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.